Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, January 6, 2022
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
Yaron Werber Initiated (ASND) at Hold and Held Target at $136 on, Jan 6th, 2022
Yaron Werber of Cowen & Co., Initiated "Ascendis Pharma A/S" (ASND) at Hold and Held Target at $136 on, Jan 6th, 2022.
Yaron has made no other calls on ASND in the last 4 months.
There are 4 other peers that have a rating on ASND. Out of the 4 peers that are also analyzing ASND, 1 agrees with Yaron's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Tazeen Ahmad of "B of A Securities" Downgraded from Strong Buy to Hold and Increased Target to $169 on, Wednesday, October 20th, 2021
These are the ratings of the 3 analyists that currently disagree with Yaron
- Derek Archila of "Wells Fargo" Initiated at Buy and Held Target at $176 on, Wednesday, December 8th, 2021
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $190 on, Monday, November 15th, 2021
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $179 on, Thursday, November 11th, 2021
